REFERENCES
- Menza M, Marin H, Opper RS (2003) Residual symptoms in depression: can treatment be symptom-specific? J Clin Psychiatry 64: 516–23.
- Paykel ES, Ramana R, Cooper Z et al (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25: 1171–80.
- Stahl SM (2004) Selectivity of SSRIs: individualising patient care through rational treatment choices. Int J Psych Clin Pract 8 (Suppl 1): 3–10.
- Tylee A, Gastpar M, Levine JP, Mendlewicz J (1999) DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 14: 139–51.
- Kasper S, Tauscher J, Willeit M et al (2002) Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette’s disorder: implications for psychopharmacology. World J Biol Psychiatry 3: 133–46.
- Kasper S, Carlsson A (2001) Selective serotonin reuptake inhibitors 1990 -2000. A decade of developments. Lundbeck publishing, Copenhagen, Denmark.
- Kasper S, Frey R, Schreinzer D (2001) Safety and tolerability of old and new antidepressants. In: den Boer J, Westenberg H (eds) Focus on psychiatry. Antidepressants: selectivity or multiplicity?. Amsterdam: Benecke: 157–69.
- Stahl S (2001) Defining and refining the pharmacology of SSRIs. In: Kasper S, Calsson A (eds) Selective serotonin reuptake inhibitors 1990 -2000. A decade of developments. Lundbeck Publishing 4–9.
- Wade A, Lemming OM, Hedegaard KB (2002) Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95–102.
- Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSR escitalopram in depressed outpatients. J Clin Psychiatry 63: 331–6.
- Lepola UM, Loft H, Reines EH (2003) Escitalopram (10 -20 mg/ day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18: 211–7.
- Gorman J, Korotzer A, Su G (2002) Efficacy comparison of escitalopram and citalopram in treatment of major depressive disorder. CNS Spectrums 7 (Suppl 1): 40–4.
- Auquier P, Robitail S, Llorca P-M, Rive B (2003) Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psych Clin Pract 7: 259–68.
- Clerc GE, Ruimy P, Verdeau-Palles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 9: 139–43.
- Thase M, Entsuah R, Rudolph R (2001) Remission rates during treatment with venlafaxine or selective-serotonin reuptake inhibitors. Br J Psychiatry 178: 234–41.
- Montgomery SA, Huusom AKT, Bothmer J (2004) A randomised study comparing escitalopram with venlafaxine XR in patients in primary care with major depressive disorder. Neuropsychobiology 50: 57–64.
- Bielksi RJ, Ventura D, Chang C-C, Korotzer A (2003) Double- blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder. Eur Neuropsychopharmaol 13 (Suppl 4): S263.